University of Colorado Hospital Eye Center, Department of Ophthalmology, Aurora, CO 80045, USA.
Curr Eye Res. 2012 Feb;37(2):101-8. doi: 10.3109/02713683.2011.631722. Epub 2011 Oct 31.
This work compares the concentration of active ingredients and preservatives in commonly used brand name versus generic glaucoma medications.
Active ingredient and benzalkonium chloride (BAK) concentrations in brand name latanoprost and dorzolamide-timolol were each compared to two generic counterparts using liquid chromatography-mass spectrometry at baseline and after exposure to 25°C and 50°C for 30 days. Micro flow imaging was used to quantify particulate material greater than one micron in diameter.
Brand name formulations contained active ingredients and BAK in concentrations that were generally in agreement with their package inserts at baseline. The two generic formulations of latanoprost contained baseline levels of active ingredients that were 10% greater than their labeled value. Generic latanoprost formulations had significant loss of active ingredient concentration after exposure to 25°C and 50°C for 30 days. Both generic and brand name dorzolamide-timolol appeared relatively resistant to degradation. BAK concentrations remained stable at 25°C but decreased in some bottles at 50°C. Bottles of both generic medications had higher levels of particulate matter compared to brand name versions.
Exposure to temperatures at the high end of the labeled value may lead to a significant decrease in concentration of active ingredients in generic formulations that could influence clinical efficacy. Re-evaluation of intraocular pressure lowering efficacy may be indicated in glaucoma patients switching from brand name to generic formulations.
本研究比较了常用品牌名与仿制药的活性成分和防腐剂浓度。
采用液相色谱-质谱法,在基线水平以及暴露于 25°C 和 50°C 30 天后,比较了品牌名拉坦前列素和多佐胺-噻吗洛尔与两种仿制药的活性成分和苯扎氯铵(BAK)浓度。采用微流成像技术定量大于 1 微米直径的颗粒物质。
品牌名制剂在基线时的活性成分和 BAK 浓度通常与产品说明书一致。两种仿制药拉坦前列素的基线活性成分水平比标签值高 10%。仿制药拉坦前列素制剂在暴露于 25°C 和 50°C 30 天后,活性成分浓度显著下降。仿制药和品牌名多佐胺-噻吗洛尔制剂相对不易降解。BAK 浓度在 25°C 时保持稳定,但在 50°C 时部分瓶中浓度降低。两种仿制药的颗粒物质水平均高于品牌名制剂。
暴露于标签值上限温度可能导致仿制药制剂中活性成分浓度显著下降,从而影响临床疗效。从品牌名制剂转换为仿制药制剂的青光眼患者,可能需要重新评估眼压降低的疗效。